SG11201906213UA - Modulating expression of polypeptides via new gene switch expression systems - Google Patents
Modulating expression of polypeptides via new gene switch expression systemsInfo
- Publication number
- SG11201906213UA SG11201906213UA SG11201906213UA SG11201906213UA SG11201906213UA SG 11201906213U A SG11201906213U A SG 11201906213UA SG 11201906213U A SG11201906213U A SG 11201906213UA SG 11201906213U A SG11201906213U A SG 11201906213UA SG 11201906213U A SG11201906213U A SG 11201906213UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- expression
- polypeptides
- blacksburg
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000002655 kraft paper Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- LZWZPGLVHLSWQX-XMMPIXPASA-N n'-(3,5-dimethylbenzoyl)-n'-[(3r)-2,2-dimethylhexan-3-yl]-2-ethyl-3-methoxybenzohydrazide Chemical compound C=1C(C)=CC(C)=CC=1C(=O)N([C@H](CCC)C(C)(C)C)NC(=O)C1=CC=CC(OC)=C1CC LZWZPGLVHLSWQX-XMMPIXPASA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229950004051 veledimex Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4635—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762444775P | 2017-01-10 | 2017-01-10 | |
US201762464958P | 2017-02-28 | 2017-02-28 | |
PCT/US2018/013196 WO2018132494A1 (en) | 2017-01-10 | 2018-01-10 | Modulating expression of polypeptides via new gene switch expression systems |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906213UA true SG11201906213UA (en) | 2019-08-27 |
Family
ID=61094600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906213UA SG11201906213UA (en) | 2017-01-10 | 2018-01-10 | Modulating expression of polypeptides via new gene switch expression systems |
Country Status (11)
Country | Link |
---|---|
US (2) | US11692194B2 (de) |
EP (2) | EP4382913A2 (de) |
JP (2) | JP7288401B2 (de) |
KR (1) | KR20190102259A (de) |
CN (1) | CN110462040A (de) |
AU (1) | AU2018207281A1 (de) |
CA (1) | CA3049652A1 (de) |
IL (2) | IL267865B1 (de) |
SG (1) | SG11201906213UA (de) |
WO (1) | WO2018132494A1 (de) |
ZA (1) | ZA201904623B (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2764471T3 (es) * | 2014-02-14 | 2020-06-03 | Univ Texas | Receptores de antígeno quimérico y procedimientos de fabricación |
WO2018112415A1 (en) | 2016-12-16 | 2018-06-21 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
SG11202003543WA (en) * | 2017-10-18 | 2020-05-28 | Intrexon Corp | Polypeptide compositions comprising spacers |
WO2019160956A1 (en) * | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
CN112543808A (zh) | 2018-06-21 | 2021-03-23 | 比莫根生物科技公司 | 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法 |
CN112714769A (zh) * | 2018-07-10 | 2021-04-27 | 普瑞赛格恩公司 | Ror-1特异性嵌合抗原受体及其用途 |
WO2020052645A1 (zh) * | 2018-09-14 | 2020-03-19 | 上海原能细胞医学技术有限公司 | 表面包含免疫调节剂的细胞及其用途 |
CN110832071A (zh) * | 2018-09-14 | 2020-02-21 | 上海原能细胞医学技术有限公司 | 表面包含免疫调节剂的细胞及其用途 |
CN114746105A (zh) * | 2018-12-14 | 2022-07-12 | 普罗维瓦疗法香港有限公司 | Il-15组合物及其使用方法 |
KR20210149090A (ko) * | 2019-04-05 | 2021-12-08 | 넥타르 테라퓨틱스 | 세포 면역요법을 향상시키기 위한 방법 |
AU2020265652A1 (en) * | 2019-04-30 | 2021-12-02 | Atara Biotherapeutics, Inc. | Antigen specific CD19-targeted CAR-T cells |
EP3753566A1 (de) * | 2019-06-21 | 2020-12-23 | Medizinische Hochschule Hannover | Viraler all-in-one-vektor für car und therapeutisches effektormolekül |
US11058725B2 (en) | 2019-09-10 | 2021-07-13 | Obsidian Therapeutics, Inc. | CA2 compositions and methods for tunable regulation |
EP3914699A4 (de) * | 2019-12-09 | 2023-03-29 | ImmunityBio, Inc. | Screening von zellklonen, die polygene transgene exprimieren, durch nichtantibiotische abhängige positive selektion |
CN115087466A (zh) * | 2019-12-12 | 2022-09-20 | 森迪生物科学公司 | 用于细胞的调控装甲的方法和组合物 |
CN115176016A (zh) * | 2020-02-19 | 2022-10-11 | 上海药明生物技术有限公司 | 增强的表达系统及其使用方法 |
JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重car-t組成物及び方法 |
TW202242117A (zh) * | 2020-12-30 | 2022-11-01 | 美商亞勞諾斯醫療公司 | 包含多順反子表現卡匣之重組載體及其使用方法 |
WO2022235811A2 (en) * | 2021-05-04 | 2022-11-10 | Editas Medicine, Inc. | Engineered cells for therapy |
CA3235894A1 (en) * | 2021-10-25 | 2023-05-04 | Brile Chung | Compositions and methods for therapeutic delivery |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
FR2593630B1 (fr) | 1986-01-27 | 1988-03-18 | Maurice Francois | Ecran d'affichage a matrice active a resistance de drain et procedes de fabrication de cet ecran |
US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
US6218525B1 (en) * | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
WO1991014695A1 (en) | 1990-03-22 | 1991-10-03 | The Salk Institute For Biological Studies | Insect retinoid receptor compositions and methods |
CA2043775A1 (en) | 1990-06-14 | 1991-12-15 | Dat P. Le | Dibenzoylakylcyanohydrazines |
CA2096222C (en) | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Bifunctional selectable fusion genes |
IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
JPH09500783A (ja) | 1993-05-21 | 1997-01-28 | ターゲッティッド ジェネティクス コーポレイション | シトシンデアミナーゼ(cd)遺伝子に基づく二機能性選択融合遺伝子 |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
ATE293699T1 (de) | 1995-03-03 | 2005-05-15 | Syngenta Participations Ag | Kontrolle der pflanzengenexpression durch rezeptor-vermittelte transaktivation in gegenwart von einem chemischen ligand |
PT814838E (pt) | 1995-03-08 | 2003-09-30 | Scripps Research Inst | Sistema de apresentacao de antigenio e activacao de celulas t |
US5785682A (en) * | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
IL126418A0 (en) | 1996-04-05 | 1999-05-09 | Salk Inst For Biological Studi | Hormone-mediated methods for modulating expression of exogenous genes and pharmaceutical compositions for modulating the same |
IL126843A (en) | 1996-05-23 | 2007-06-17 | Scripps Research Inst | Mhc class ii antigen-presenting systems and methods for activating cd4+t cells in vitro |
WO1998040510A1 (en) | 1997-03-11 | 1998-09-17 | Regents Of The University Of Minnesota | Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
CA2296093A1 (en) | 1997-07-10 | 1999-01-21 | The Salk Institute For Biological Studies | Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression |
US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
WO2000078951A1 (en) * | 1999-06-18 | 2000-12-28 | Ariad Gene Therapeutics, Inc. | Chimeric oca-b transcription factors |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
AU1100201A (en) | 1999-10-28 | 2001-05-08 | Board Of Trustees Of The Leland Stanford Junior University | Methods of in vivo gene transfer using a sleeping beauty transposon system |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
JP2004500095A (ja) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | 細胞の同時の刺激および濃縮 |
AU2001249315A1 (en) | 2000-03-22 | 2001-10-03 | Rheogene, Inc. | Ecdysone receptor-based inducible gene expression system |
US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
MXPA03007492A (es) | 2001-02-20 | 2004-10-15 | Rheogene Holdings Inc | Receptores de retinoide x quimerico y su uso en un sistema de expresion de gen inducible basado en receptor de ecdisona novedoso. |
DK1373470T3 (da) | 2001-02-20 | 2013-07-29 | Intrexon Corp | Hidtil ukendte substitutionsmutantreceptorer og deres anvendelse i et cellekernereceptorbaseret inducerbart genekspressionssystem |
ATE545705T1 (de) | 2001-02-20 | 2012-03-15 | Intrexon Corp | Neues induzierbares genexpressionssystem auf ecdysonrezeptor/invertebraten-retinoid-x-rezept r-basis |
US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
US9249207B2 (en) | 2001-02-20 | 2016-02-02 | Intrexon Corporation | Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system |
JP2005507247A (ja) | 2001-09-26 | 2005-03-17 | レオジーン・ホールディングス,インコーポレーテッド | コナジラミエクジソン受容体核酸、ポリペプチド、およびそれらの使用 |
MXPA04002810A (es) | 2001-09-26 | 2005-06-06 | Rheogene Holdings Inc | Acidos nucleicos receptores de ecdisona de saltarilla, polipeptidos, y sus usos. |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
AU2003231048A1 (en) | 2002-04-22 | 2003-11-03 | Regents Of The University Of Minnesota | Transposon system and methods of use |
US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US8802643B1 (en) | 2003-05-30 | 2014-08-12 | University Of South Florida | Method for the treatment of malignancies |
US7985739B2 (en) | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
WO2005118788A2 (en) | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
DE602005022595D1 (de) | 2004-06-29 | 2010-09-09 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
US7847064B2 (en) * | 2004-07-09 | 2010-12-07 | Donald Danforth Plant Science Center | Methods and compositions for regulating gene expression in plant cells |
AU2005336093B2 (en) | 2004-10-08 | 2011-02-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Adoptive immunotherapy with enhanced T lymphocyte survival |
NZ563263A (en) | 2005-05-17 | 2010-04-30 | Univ Connecticut | Composition and methods for immunomodulation in an organism |
EP1777294A1 (de) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine |
MX2008011302A (es) | 2006-03-01 | 2008-11-04 | Janssen Pharmaceutica Nv | Tratamiento de cancer que combina agente de linfodeplecion con linfocitos t citotoxicos y citocinas. |
EP2044115A2 (de) * | 2006-06-12 | 2009-04-08 | Receptor Biologix, Inc. | Für die oberflächenrezeptoren von pan-zellen spezifische therapeutika |
US8124408B2 (en) | 2006-10-04 | 2012-02-28 | Janssen Pharmaceutica N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
WO2008103474A1 (en) | 2007-02-20 | 2008-08-28 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constituent expression of costimulatory ligands on indirectly transmitted T lymphocytes |
NZ616254A (en) | 2007-06-27 | 2015-04-24 | Us Sec Dep Of Health And Human Services | Complexes of il-15 and il-15ralpha and uses thereof |
WO2009003671A2 (en) | 2007-07-04 | 2009-01-08 | Max-Delbrück-Centrum für Molekulare Medizin | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
EP2205249B1 (de) | 2007-09-28 | 2018-11-07 | Intrexon Corporation | Therapeutische genschalterkonstrukte und bioreaktoren zur expression biotherapeutischer moleküle und ihre verwendung |
AU2008311292B9 (en) | 2007-10-08 | 2014-10-09 | Intrexon Corporation | Engineered dendritic cells and uses for the treatment of cancer |
KR101695035B1 (ko) * | 2008-03-14 | 2017-01-23 | 인트렉손 코포레이션 | 스테로이드성 리간드 및 유전자 스위치 조절에서 이의 용도 |
US9492482B2 (en) | 2008-10-08 | 2016-11-15 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
AU2010241864B2 (en) * | 2009-04-30 | 2014-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
JP5508625B2 (ja) | 2009-12-14 | 2014-06-04 | トヨタ自動車株式会社 | 車両の制御装置及び車両の制御方法 |
KR20180108886A (ko) | 2010-03-23 | 2018-10-04 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터,상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
US9331524B1 (en) | 2010-07-03 | 2016-05-03 | Best Energy Reduction Technologies, Llc | Method, system and apparatus for monitoring and measuring power usage |
JP6189754B2 (ja) | 2011-03-04 | 2017-08-30 | イントレキソン コーポレーション | タンパク質を条件的に発現するベクター |
KR102108521B1 (ko) * | 2011-03-25 | 2020-05-11 | 아이크노스 사이언스 에스. 아. | 헤테로 이량체 면역글로불린 |
CN103596981B (zh) * | 2011-04-08 | 2017-06-16 | 美国卫生和人力服务部 | 抗‑表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途 |
US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
WO2014159415A1 (en) | 2013-03-12 | 2014-10-02 | Bio-Rad Laboratories, Inc. | Colloidal coomassie stain |
KR102095700B1 (ko) | 2013-05-14 | 2020-04-01 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (car) t-세포의 인간 적용 |
CA2913052A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
US10010608B2 (en) * | 2013-05-31 | 2018-07-03 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
US20170002378A1 (en) * | 2013-11-29 | 2017-01-05 | Ucb Biopharma Sprl | Synthetic Promoters |
JP2017501712A (ja) | 2013-12-18 | 2017-01-19 | イントレキソン コーポレーション | 単鎖il−12核酸、ポリペプチド、およびそれらの使用 |
RS62038B1 (sr) * | 2014-02-10 | 2021-07-30 | Merck Patent Gmbh | Ciljana tgf beta inhibicija |
US9814215B2 (en) | 2014-03-11 | 2017-11-14 | Little Big Cat, Inc. | Pet toy with telescoping wand with metallic wire |
US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
CN107405411A (zh) * | 2014-05-01 | 2017-11-28 | 华盛顿大学 | 使用腺病毒载体的体内基因改造 |
US10428305B2 (en) | 2014-05-15 | 2019-10-01 | National University Of Singapore | Modified natural killer cells that express IL15 and uses thereof |
SG11201609960QA (en) | 2014-06-02 | 2016-12-29 | Us Health | Chimeric antigen receptors targeting cd-19 |
WO2015188191A1 (en) | 2014-06-06 | 2015-12-10 | Wong Wilson W | Dna recombinase circuits for logical control of gene expression |
ES2811974T3 (es) | 2014-07-29 | 2021-03-15 | Novartis Ag | Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones |
TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
WO2016048903A1 (en) | 2014-09-22 | 2016-03-31 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
CA2964785A1 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
PL3268470T3 (pl) | 2015-03-11 | 2021-06-14 | Board Of Regents, The University Of Texas System | Polipeptydy transpozazy i ich zastosowania |
JP2018517415A (ja) * | 2015-06-10 | 2018-07-05 | ナントクエスト インコーポレイテッド | がんを処置するための改変nk−92細胞 |
EP3352779A4 (de) | 2015-09-25 | 2020-02-19 | Altor BioScience Corporation | Interleukin-15-superagonist zur signifikanten verstärkung der transplantat-gegen-tumor-aktivität |
CA3001590A1 (en) | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
WO2017079703A1 (en) * | 2015-11-05 | 2017-05-11 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
CN108713025A (zh) | 2015-11-11 | 2018-10-26 | 英特拉克森公司 | 用于治疗心脏病况和其他病理的从单个载体表达多种生物活性多肽的组合物和方法 |
CN106967685B (zh) * | 2016-01-13 | 2020-06-02 | 北京马力喏生物科技有限公司 | 共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途 |
WO2017177063A1 (en) | 2016-04-06 | 2017-10-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of heterodimeric il-15 in adoptive cell transfer |
PL3377637T3 (pl) * | 2016-04-08 | 2020-09-07 | Krystal Biotech, Inc. | Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry |
AU2018281316B2 (en) | 2017-06-07 | 2024-05-30 | Precigen, Inc. | Expression of novel cell tags |
-
2018
- 2018-01-10 EP EP24156133.1A patent/EP4382913A2/de active Pending
- 2018-01-10 CA CA3049652A patent/CA3049652A1/en active Pending
- 2018-01-10 US US15/867,500 patent/US11692194B2/en active Active
- 2018-01-10 AU AU2018207281A patent/AU2018207281A1/en active Pending
- 2018-01-10 CN CN201880017197.6A patent/CN110462040A/zh active Pending
- 2018-01-10 KR KR1020197023025A patent/KR20190102259A/ko not_active Application Discontinuation
- 2018-01-10 EP EP18702387.4A patent/EP3568474A1/de active Pending
- 2018-01-10 JP JP2019537292A patent/JP7288401B2/ja active Active
- 2018-01-10 WO PCT/US2018/013196 patent/WO2018132494A1/en unknown
- 2018-01-10 IL IL267865A patent/IL267865B1/en unknown
- 2018-01-10 IL IL310711A patent/IL310711A/en unknown
- 2018-01-10 SG SG11201906213UA patent/SG11201906213UA/en unknown
-
2019
- 2019-07-15 ZA ZA2019/04623A patent/ZA201904623B/en unknown
-
2020
- 2020-05-22 US US16/881,871 patent/US11946054B2/en active Active
-
2023
- 2023-02-10 JP JP2023018898A patent/JP2023065438A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3049652A1 (en) | 2018-07-19 |
IL267865A (en) | 2019-09-26 |
JP2023065438A (ja) | 2023-05-12 |
EP3568474A1 (de) | 2019-11-20 |
EP4382913A2 (de) | 2024-06-12 |
US20200283778A1 (en) | 2020-09-10 |
US20180291384A1 (en) | 2018-10-11 |
IL310711A (en) | 2024-04-01 |
AU2018207281A1 (en) | 2019-07-18 |
IL267865B1 (en) | 2024-03-01 |
KR20190102259A (ko) | 2019-09-03 |
US11946054B2 (en) | 2024-04-02 |
JP2020513777A (ja) | 2020-05-21 |
JP7288401B2 (ja) | 2023-06-07 |
CN110462040A (zh) | 2019-11-15 |
WO2018132494A1 (en) | 2018-07-19 |
US11692194B2 (en) | 2023-07-04 |
ZA201904623B (en) | 2023-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906213UA (en) | Modulating expression of polypeptides via new gene switch expression systems | |
SG11201804178YA (en) | Pd1 and/or lag3 binders | |
SG11201907713WA (en) | Nucleic acid based data storage | |
SG11201901563UA (en) | De novo synthesized nucleic acid libraries | |
SG11201906264YA (en) | Improved serum albumin binders | |
SG11201909724RA (en) | Systems and processes for conversion of crude oil | |
SG11201908784TA (en) | Improved antigen binding receptor formats | |
SG11201808196UA (en) | Neoantigens and methods of their use | |
SG11201908796XA (en) | Improved antigen binding receptors | |
SG11201811025VA (en) | Systems and methods for automated annotation and screening of biological sequences | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201908319WA (en) | Methods and systems for printing biological material | |
SG11201906341XA (en) | Improved serum albumin binders | |
SG11201901221YA (en) | Methods for detecting aav | |
SG11201407508RA (en) | Encoding and decoding based on blending of sequences of samples along time | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201906142QA (en) | Conversion of crude oil to aromatic and olefinic petrochemicals | |
SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
SG11201407818PA (en) | High-capacity storage of digital information in dna | |
SG11201906152RA (en) | Conversion of crude oil to aromatic and olefinic petrochemicals | |
SG11201407343XA (en) | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof | |
SG11201907671XA (en) | Systems and methods for cracking hydrocarbon streams such as crude oils utilizing catalysts which include zeolite mixtures | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same |